Back |
home / stock / hmtxf / hmtxf message board
Subject | By | Source | When |
---|---|---|---|
IR CONSULTING HEAD: The companys lead candidate for phase 2 clinical-stage trial is doing wonders in | IR_CONSULTING_HEAD | investorshangout | 04/13/2022 2:20:21 PM |
IR CONSULTING HEAD: The company's market capitalization is at $10.2M, holding the water from floodin | IR_CONSULTING_HEAD | investorshangout | 04/13/2022 2:18:58 PM |
IR CONSULTING HEAD: Hemostemix has completed a detailed audit of the data received to ensure the aut | IR_CONSULTING_HEAD | investorshangout | 04/13/2022 2:17:38 PM |
IR CONSULTING HEAD: The ongoing dispute between aspiring health science has finally met its end as a | IR_CONSULTING_HEAD | investorshangout | 04/13/2022 2:15:57 PM |
IR CONSULTING HEAD: Hemostemix is a biotechnology-based clinical-stage company listed on the OTC mar | IR_CONSULTING_HEAD | investorshangout | 04/13/2022 2:06:28 PM |
News, Short Squeeze, Breakout and More Instantly...
Calgary, Alberta--(Newsfile Corp. - March 7, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the non-exclusive engagement of Oak Hill Asset Management Inc. ("OHAM"), an Exempt Market Dealer to provide capital markets advice rel...
Calgary, Alberta--(Newsfile Corp. - February 6, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Journal of Biomedical Research and Environmental Sciences published the Company's Phase II randomized clinical trial results ...
Calgary, Alberta--(Newsfile Corp. - December 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to like to clarify its press release of October 3, 2023. It refered to the private placement of $320,125 . The Company closed the financing i...